NCT06681246Recruiting
The Role of Microbiome in Recurrent Obesity Before and After Antibiotic/Placebo Treatment
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
This past century witnessed a significant increase in the prevalence of obesity. Successful weight loss maintenance is defined as losing at least 10% of the initial body weight and maintaining it for at least one year. However, keeping a low body weight is rarely maintained, as 80% of people who lost 10% of their body weight will return to their initial weight within a year. Although there is no agreement as to what contributes to the recurrent weight regain phenomenon (also known as 'weight cycling' or 'yo-yo diet'), it is strongly associated with the risk of developing metabolic risk factors and their complications, including heart disease and all-cause mortality. Altering the gut microbiota is one method to treat disease states associated with gut bacteria. Antibiotics consumption is known to influence host glycemic response through changes induced in microbiome composition and function. Therefore, it may be a possible pathway to jumpstart changes in the gut microbiota. This study will determine whether microbiome modulation might be a possible future target against recurrent obesity in humans and whether orally administered antibiotic treatment post-weight loss might be an effective intervention to prevent weight regain.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 6 Nov 2024
- Start date
- 11 Dec 2024
- Primary completion date
- Dec 2026
- Lead sponsor
- Weizmann Institute of Science
- Diseases
- Obesity
- NCT number
- NCT06681246
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 11 Dec 2024 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Consumption of antibiotics/probiotics/oral antifungals 2 months prior to the first day of the experiment.
- Pregnancy, fertility treatments, breastfeeding women six months prior to enrollment and during the study.
- Bariatric surgery.
- Weight loss attempts 6 months prior to the first day of the experiment - using weight loss medication.
- Drastic changes in nutritional habits six months prior to the first day of the study - to the discretion of the study team.
Other illness
- Chronic disease, to the discretion of the study team (e.g. AIDS, Cushing syndrome, CKD, acromegaly etc.)
- Cancer and recent anticancer treatment
- Psychiatric disorders, to the discretion of the study team.
- Coagulation disorders
- IBD (inflammatory bowel diseases)
- Eating disorders (Anorexia nervosa. Bulimia nervosa. Binge eating disorder, Night eating syndrome).
- Allergy to penicillin.
- History of CDI
- Liver disease
- History of serious unresolved diarrhea in response to antibiotic treatment to the discretion of the study doctor.
Other
- Alcohol or substance abuse
- Life threatening reaction after consumption of cephalosporins.
Who the study is looking for
- 28 \< BMI\< 40
- Age - 18-65
- Capable of working with a smartphone application
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Weizmann Institute of Science Coordinator of this site? Confirm its status | Rehovot | Israel | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.